148 related articles for article (PubMed ID: 17229638)
1. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.
Marijt E; Wafelman A; van der Hoorn M; van Bergen C; Bongaerts R; van Luxemburg-Heijs S; van den Muijsenberg J; Wolbers JO; van der Werff N; Willemze R; Falkenburg F
Haematologica; 2007 Jan; 92(1):72-80. PubMed ID: 17229638
[TBL] [Abstract][Full Text] [Related]
2. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.
Falkenburg JH; Faber LM; van den Elshout M; van Luxemburg-Heijs SA; Hooftman-den Otter A; Smit WM; Voogt PJ; Willemze R
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):305-9. PubMed ID: 8280712
[TBL] [Abstract][Full Text] [Related]
3. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.
Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R
Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707
[TBL] [Abstract][Full Text] [Related]
4. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
[TBL] [Abstract][Full Text] [Related]
5. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
6. Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation.
Montagna D; Maccario R; Locatelli F
Int J Immunogenet; 2008 Aug; 35(4-5):389-93. PubMed ID: 18976444
[TBL] [Abstract][Full Text] [Related]
7. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors.
Montagna D; Maccario R; Montini E; Tonelli R; Lisini D; Pagani S; Comoli P; Moretta A; Assirelli E; Basso S; Vitiello A; Pession A; Locatelli F
Exp Hematol; 2003 Nov; 31(11):1031-8. PubMed ID: 14585366
[TBL] [Abstract][Full Text] [Related]
8. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.
Faber LM; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Exp Med; 1992 Nov; 176(5):1283-9. PubMed ID: 1402674
[TBL] [Abstract][Full Text] [Related]
9. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
10. Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.
Hoogendoorn M; Olde Wolbers J; Smit WM; Schaafsma MR; Jedema I; Barge RM; Willemze R; Falkenburg JH
Clin Cancer Res; 2005 Jul; 11(14):5310-8. PubMed ID: 16033850
[TBL] [Abstract][Full Text] [Related]
11. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
[TBL] [Abstract][Full Text] [Related]
12. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH
Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118
[TBL] [Abstract][Full Text] [Related]
13. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
14. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
[TBL] [Abstract][Full Text] [Related]
15. Generation of alloreactive anti-leukemic cytotoxic T lymphocytes with attenuated GVHD properties from haploidentical parents in childhood acute lymphoblastic leukemia.
Jurickova I; Waller EK; Yeager AM; Boyer MW
Bone Marrow Transplant; 2002 Nov; 30(10):687-97. PubMed ID: 12420208
[TBL] [Abstract][Full Text] [Related]
16. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation.
Kurokawa T; Fischer K; Bertz H; Hoegerle S; Finke J; Mackensen A
Int J Cancer; 2002 Sep; 101(1):52-60. PubMed ID: 12209588
[TBL] [Abstract][Full Text] [Related]
18. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD
Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018
[TBL] [Abstract][Full Text] [Related]
19. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].
Schattenberg AV; van de Wiel-van Kemenade E; Bär BM; Geurts van Kessel AH; van der Maazen RW; de Witte TJ
Ned Tijdschr Geneeskd; 1996 Oct; 140(42):2087-91. PubMed ID: 8965951
[TBL] [Abstract][Full Text] [Related]
20. Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells.
Bao H; Wu D
Curr Stem Cell Res Ther; 2017; 12(3):188-196. PubMed ID: 28025936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
